Plasma α-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients

American Journal of Nephrology

Volumn 28, Issue 6, 2008, Pages 871-878

  Nakayama, Keisuke ^a,d   Nakayama, Masaaki ^a   Iwabuchi, Masashi ^b   Terawaki, Hiroyuki ^a   Sato, Toshinobu ^b   Kohno, Masahiro ^c   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d NONE   (Japan)

Author keywords

3 Deoxyglucosone; Chronic kidney disease; Glyoxal; Liquid chromatography mass spectrometry; Methylglyoxal; Oxoaldehyde

Indexed keywords

3 DEOXYGLUCOSONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYOXAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METHYLGLYOXAL;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADULT; AGED; ALDEHYDES; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MASS SPECTROMETRY; MIDDLE AGED; RENAL DIALYSIS;

EID: 53549106326     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139653     Document Type: Article

References (44)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-1315.
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
4. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D: Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant 2000;15:69-80.
5. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-753.
6. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55.
7. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002;13:1918-1927.
8. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-2356.
9. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 2000;35:365-380.
10. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC: Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256:308-315.
11. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2000;13:813-820.
12. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9.
13. Stitt AW, Jenkins AJ, Cooper ME: Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002;11:1205-1223.
14. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999;55:389-399.
15. Makita Z, Bucala R, Rayfield EJ, Fuh H, Manogue KR, Cerami A, Vlassara H, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA: Reactive glycosylation end-products in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519-1522.
16. Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;15:109-116.
17. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A: Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003;375:581-592.
18. Ahmed N, Dobler D, Dean M, Thornalley PJ: Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 2005;280:5724-5732.
19. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ: Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005;48:1590-1603.
20. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 2001;44:129-146.
21. Akhand AA, Hossain K, Mitsui H, Kato M, Miyata T, Inagi R, Du J, Takeda K, Kawamoto Y, Suzuki H, Kurokawa K, Nakashima I: Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med 2001;31:20-30.
22. Fukunaga M, Miyata S, Liu BF, Miyazaki H, Hirota Y, Higo S, Hamada Y, Ueyama S, Kasuga M: Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. Biochem Biophys Res Commun 2004;30:689-695.
23. Di Loreto S, Caracciolo V, Colafarina S, Sebastiani P, Gasbarri A, Amicarelli F: Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. Brain Res 2004;1006:157-167.
24. Che W, Asahi M, Takahashi M, Kaneto H, Okado A, Higashiyama S, Taniguchi N: Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells. The involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes. J Biol Chem 1997;272:18453-18459.
25. Kikuchi S, Shinpo K, Moriwaka F, Makita Z, Miyata T, Tashiro K: Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons: synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases. J Neurosci Res 1999;57:280-289.
26. Dobler D, Ahmed N, Song L, Eboigbodin KE, Thornalley PJ: Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 2006;55:1961-1969.
27. Berlanga J, Cibrian D, Guillen I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, Thornalley PJ: Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 2005;109:83-95.
28. Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K: Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 1999;256:89-93.
29. Randell EW, Vasdev S, Gill V: Measurement of methylglyoxal in rat tissues by electrospray ionization mass spectrometry and liquid chromatography. J Pharmacol Toxicol Methods 2005;51:153-157.
30. National Institute of Neurological Disorders and Stroke Ad Hoc Committee: Classification of cerebrovascular disease III. Stroke 1990;21:637-676.
31. Nemet I, Turk Z, Duvnjak L, Car N, Varga-Defterdarovic L: Humoral methylglyoxal level reflects glycemic fluctuation. Clin Biochem 2005;38:379-383.
32. Thornalley PJ: The glyoxalase system in health and disease. Mol Aspects Med 1993;14:287-371.
33. Golej J, Hoeger H, Radner W, Unfried G, Lubec G: Oral administration of methylglyoxal leads to kidney collagen accumulation in the mouse. Life Sci 1998;63:801-807.
34. Nakayama M, Saito K, Sato E, Nakayama K, Terawaki H, Ito S, Kohno M: Radical generation by the non-enzymatic reaction of methylglyoxal and hydrogen peroxide. Redox Rep 2007;12:125-133.
35. Knecht KJ, Feather MS, Baynes JW: Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. Arch Biochem Biophys 1992;294:130-137.
36. Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, Sakai M, Shoda H, Oimomi M, Kasuga M: Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction. J Biol Chem 1994;269:20275-20280.
37. Niwa T, Takeda N, Miyazaki T, Yoshizumi H, Tatematsu A, Maeda K, Ohara M, Tomiyama S, Niimura K: Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic patients. Nephron 1995;69:438-443.
38. Lapolla A, Flamini R, Lupo A, Arico NC, Rugiu C, Reitano R, Tubaro M, Ragazzi E, Seraglia R, Traldi P: Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis. Ann NY Acad Sci 2005;1043:217-224.
39. McLellan AC, Thornalley PJ, Benn J, Sonksen PH: Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 1994;87:21-29.
40. Turk Z, Nemet I, Varga-Defteardarovic L, Car N: Elevated level of methylglyoxal during diabetic ketoacidosis and its recovery phase. Diabetes Metab 2006;32:176-180.
41. Nemet I, Varga-Defterdarovic L, Turk Z: Preparation and quantification of methylglyoxal in human plasma using reverse-phase high-performance liquid chromatography. Clin Biochem 2004;37:875-881.
42. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS: Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999;48:198-202.
43. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y: Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996;49:861-867.
44. Hasuike Y, Nakanishi T, Otaki Y, Nanami M, Tanimoto T, Taniguchi N, Takamitsu Y: Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am J Kidney Dis 2002;40:464-471.